iShares Russell 2000 ETF Newsroom

Blueprint Medicines Analyst Ratings

BenzingaJul 12 13:18 ET

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115

BenzingaJul 12 13:18 ET

Insmed Analyst Ratings

BenzingaJul 12 13:02 ET

Blueprint Medicines (BPMC) Receives a Hold From Morgan Stanley

TipRanksJul 12 08:41 ET

Barclays Keeps Their Buy Rating on Insmed (INSM)

TipRanksJul 12 04:19 ET

Analyst Ratings For Abercrombie & Fitch

BenzingaJul 11 09:03 ET

Abercrombie & Fitch Analyst Ratings

BenzingaJul 11 07:48 ET

Lantheus Holdings Analyst Ratings

BenzingaJul 11 07:24 ET

Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)

TipRanksJul 11 06:42 ET

Truist Securities Adjusts Price Target on Lantheus Holdings to $141 From $96, Maintains Buy Rating

MT NewswiresJul 11 05:19 ET

Lantheus Buy Rating Affirmed Amid Favorable CMS Changes and Strong Market Position

TipRanksJul 10 14:59 ET

Goldman Sachs Raises Price Target on Insmed to $102 From $74, Maintains Buy Rating

MT NewswiresJul 10 11:52 ET

Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $102

BenzingaJul 10 11:27 ET

Goldman Sachs Adjusts Price Target on Sprouts Farmers Market to $89 From $78, Maintains Buy Rating

MT NewswiresJul 10 10:34 ET

FTAI Aviation Downgraded at Wolfe Research

Seeking AlphaJul 10 09:19 ET

Sprouts Farmers Market Analyst Ratings

BenzingaJul 10 08:39 ET

FTAI Aviation Analyst Ratings

BenzingaJul 10 06:18 ET

Insmed Analyst Ratings

BenzingaJul 9 12:24 ET

Truist Financial Sticks to Its Buy Rating for Fluor (FLR)

TipRanksJul 8 22:27 ET

Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating

MT NewswiresJul 8 09:27 ET